rAAV2-ND4
PreclinicalGene therapy
rAAV2-ND4 is one of 4 small molecule programs targeting Leber hereditary optic neuropathy. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in Gene Therapy
#DrugCompanyPhaseTrials
1Busulfex
Akero TherapeuticsPhase 2
BMN 333
BioMarin PharmaceuticalPhase 2
rAAV2-ND4
BBin Li
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Neuropathy1 trial
Gene Therapy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rAAV2-ND4. EMBL-EBI & Wellcome Sanger Institute.
- [4]